Loading the catalog…
Loading the catalog…
早盘创新药概念震荡下挫,艾力斯 20cm 跌停,百普赛斯跌超 10%,亚虹医药、迈威生物等多股跟跌。受艾力斯伏美替尼 III 期临床试验未达到主要研究终点的消息影响,其合作伙伴 ArriVent 于 10 月 6 日在美股单日暴跌 47%。
What RADAR observed and classified to build this opportunity. It is what the source published, not a verification that the offer is still active.
创新药概念下挫 艾力斯 20cm 跌停 其新药临床未达终点. 早盘创新药概念震荡下挫,艾力斯 20cm 跌停,百普赛斯跌超 10%,亚虹医药、迈威生物等多股跟跌。受艾力斯伏美替尼 III 期临床试验未达到主要研究终点的消息影响,其合作伙伴 ArriVent 于 10 月 6 日在美股单日暴跌 47%。
Open sourceThe catalog shows persisted RADAR opportunities. Storage availability does not mean sources are verified or offers are active.